Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies

Leonidas C. Platanias*, Mark J. Ratain, Sheila O'brien, Richard A. Larson, James W. Vardiman, Jill P. Shaw, Stephanie F. Williams, Joseph M. Baron, Karen Parker, Thasia G. Woodworth

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB<sub>486</sub>IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences